Results 81 to 90 of about 1,721 (143)

Eligibility of Outpatients with Chronic Heart Failure for Vericiguat and Omecamtiv Mecarbil: From Clinical Trials to the Real-World Practice [PDF]

Background: Several drugs are emerging as potential therapeutic resources in the context of chronic heart failure (CHF), although their impact on daily clinical practice remains unknown.
Falagario, Alessio, Naccarati, Maria Ludovica, Andrea Igoren Guaricci, Gianluca Pontone, Maria Ludovica Naccarati, Marco Maria Dicorato, Daniela Santoro, Santobuono, Vincenzo Ezio, Ciccone, Marco Matteo, Santoro, Daniela, Marco Matteo Ciccone, Basile, Paolo, Guaricci, Andrea Igoren, Paolo Basile, Carella, Maria Cristina, Vincenzo Ezio Santobuono, Dicorato, Marco Maria, Alessio Falagario, Pontone, Gianluca, Maria Cristina Carella, Francesco Monitillo, Monitillo, Francesco   +21 more
core   +1 more source

Vericiguat in patients with heart failure and implantable cardioverter-defibrillator

Drugs in Context
Background: This analysis assesses the effectiveness and tolerability profile of vericiguat in patients with heart failure with reduced ejection fraction (HFrEF) and implantable cardioverter-defibrillator, with an emphasis on the emergence of ventricular
Carlos Escobar, Jesús Saldaña, José Luis Merino, Rafael Peinado   +3 more
doaj   +1 more source

Vericiguat prevents high glucose-mediated impaired vascular smooth muscle cGMP production and vasorelaxation

Scientific Reports
Normal endothelial cell dependent vascular smooth muscle cell function is mediated by nitric oxide (NO), which stimulates soluble guanylyl cyclase (sGC) production of the second messenger cyclic guanosine monophosphate (cGMP) leading to increased protein
David Polhemus, Diego Almodiel, Tarek Harb, Efthymios Ziogos, Nuria Amat-Codina, Mark Ranek, Lakshmi Santhanam, Gary Gerstenblith, Thorsten M. Leucker   +8 more
doaj   +1 more source

New Therapeutics for Heart Failure Worsening: Focus on Vericiguat

Heart failure (HF) is a syndrome characterized by signs and symptoms resulting from structural or functional cardiac abnormalities, confirmed by elevated natriuretic peptides or evidence of congestion.
Patrizia Russo, Laura Vitiello, Giuseppe M. C. Rosano, Maurizio Volterrani, Carlo Tomino, Stefano Bonassi, Francesca Milani   +6 more
core   +1 more source

Evaluating haemodynamic changes: vericiguat in patients with heart failure with reduced ejection fraction

ESC Heart Failure
Aims Vericiguat has been used to treat patients with heart failure with reduced ejection fraction (HFrEF) who demonstrated worsening heart failure despite treatment with other guideline‐directed medical therapies.
Hideaki Suzuki, Takumi Inoue, Yousuke Terui, Kouki Takeuchi, Kai Susukita, Marina Arai, Haruka Sato, Taijyu Satoh, Saori Yamamoto, Nobuhiro Yaoita, Shunsuke Tatebe, Hideka Hayashi, Kotaro Nochioka, Hiroyuki Takahama, Satoshi Yasuda   +14 more
doaj   +1 more source

Effects of Vericiguat on Peripheral Vascular Function and Resting/Exercise Hemodynamics in Patients With Heart Failure With Reduced Ejection Fraction: An Exploratory Pilot Study

Journal of Cardiovascular Pharmacology and Therapeutics
Background Vericiguat improves outcomes in heart failure with reduced ejection fraction (HFrEF), but its vascular and hemodynamic effects remain unclear.
Yohei Funauchi MD, Toru Takase MD, PhD, Kazuyoshi Kakehi MD, PhD, Masafumi Ueno MD, PhD, Gaku Nakazawa MD, PhD   +4 more
doaj   +1 more source

Role of vericiguat in management of patients with heart failure with reduced ejection fraction after worsening episode

ESC Heart Failure
Worsening heart failure (HF) is a vulnerable period in which the patient has a markedly high risk of death or HF hospitalization (up to 10% and 30%, respectively, within the first weeks after episode). The prognosis of HF patients can be improved through
Aleix Olivella, Luis Almenar‐Bonet, Pedro Moliner, Emmanuel Coloma, Antoni Martínez‐Rubio, Marco Paz Bermejo, Ramon Boixeda, German Cediel, Ana Belén Méndez Fernández, Lorenzo Facila Rubio   +9 more
doaj   +1 more source

Initiation of vericiguat and short-term cardiovascular function improvement in heart failure patients with and without worsened renal function

Frontiers in Cardiovascular Medicine
BackgroundRecognized as a global health issue, Heart failure (HF) is a complex clinical syndrome and often worsening due to cardiorenal interactions. vericiguat, a novel soluble guanylate cyclase (sGC) stimulator, is approved for treating heart failure ...
Xinyu Zhang, Xinyu Zhang, Xinyu Zhang, Wei Zhou, Hui Liu, Chengquan Zhang, Chengquan Zhang, Chengquan Zhang, Yifan Qi, Yifan Qi, Yifan Qi, Xiao Yuan, Xiao Yuan, Zuyi Yuan, Zuyi Yuan, Lizhe Sun, Lizhe Sun, Jianqing She, Jianqing She, Bowen Lou, Bowen Lou   +20 more
doaj   +1 more source

Vericiguat and Cardiovascular Outcomes in Heart Failure by Baseline Diabetes Status:Insights From the VICTORIA Trial [PDF]

Background: Type 2 diabetes mellitus (T2DM) significantly worsens heart failure (HF) prognosis. Objectives: This study sought to investigate the impact of T2DM on outcomes in patients enrolled in VICTORIA and assess the efficacy of vericiguat in patients
Escobedo, Jorge, Armstrong, Paul W., Lam, Carolyn S.P., Refsgaard, Jens, Ponikowski, Piotr, Khan, Muhammad Shahzeb, Roessig, Lothar, Blaustein, Robert O., Voors, Adriaan A., Lewis, Basil S., Reyes, Eugene, Anstrom, Kevin J., Butler, Javed, Young, Rebecca   +13 more
core   +1 more source

Clinical profile, associated events and safety of vericiguat in a real‐world cohort: The VERITA study

ESC Heart Failure
Aims The aim of this study was to determine the clinical profile, associated events and safety of vericiguat in a real‐world cohort of patients with heart failure with reduced ejection fraction (HFrEF).
Mario Galván Ruiz, Miguel Fernández de Sanmamed Girón, María delVal Groba Marco, Lorena Rojo Jorge, Claudia Peña Saavedra, Elvira Martín Bou, Rubén Andrade Guerra, Eduardo Caballero Dorta, Antonio García Quintana   +8 more
doaj   +1 more source